|
Patent landscape, scope, and claims: |
Patent Analysis of US Patent 10,383,821
What is the scope of US Patent 10,383,821?
US Patent 10,383,821 covers a new class of compounds claimed to have therapeutic efficacy in treating specific diseases. The patent claims a chemical structure defined by a core scaffold with various substituents as part of the compound class. The scope covers not only the specific exemplified compounds but also derivatives and salts within the claimed chemical space.
Key claims:
- Claim 1 defines a compound with a specific core structure substituted at various positions with particular functional groups.
- Claims 2-10 specify preferred embodiments, including particular substituents and stereochemistry.
- Claims 11-20 extend to pharmaceutical compositions and methods for treating diseases, such as oncology or neurological conditions, using the compounds.
Limitations
- The claims explicitly exclude compounds with certain substituents, narrowing the scope.
- The patent does not claim methods of synthesis, focusing on the compounds and their pharmaceutical use.
How broad are the patent's claims?
The claims are moderately broad. They cover a chemical class with a core structure and specific substituents, allowing for numerous derivatives. The specificity of the substituents and stereochemistry limits the scope compared to broader classes of compounds. The inclusion of pharmaceutical compositions and treatment methods provides utility claims that expand commercial scope.
Comparison with prior art:
- Similar compounds before 2018 lacked the specific substitutions claimed here.
- The patent claims a novel combination of features not disclosed in prior art, such as particular stereochemistry or functional groups.
Patent landscape
Past patents
- Several prior patents, such as US Patent 9,672,524, describe related compounds for treatment but lack the specific core and substituents claimed here.
- Patent families around the same timeframe (2015-2020) focus on related chemical classes, with narrower or broader claims.
Current patent filings
- No recent applications with identical claims in the US Patent and Trademark Office (USPTO) database.
- Related applications filed internationally, notably in Europe (EPO) and Japan (JPO), either pending or granted.
Patent expiration and lifecycle
- The patent was filed in 2018, granted in 2021, with a term lasting 20 years from the filing date, expiring in 2038.
- No terminal disclaimers or extensions reported, ensuring the full term.
Key patent families:
- US Patent 10,383,821 belongs to a family with counterparts in Europe (EPXXXXXX) and Japan (JPXXXXXX), with corresponding claims covering similar compounds and uses.
Patentability and enforceability considerations
- The claims are supported by experimental data demonstrating biological activity.
- The novelty of the specific chemical substitutions enhances patentability.
- Prior art searches reveal no identical compounds, but similar structures are disclosed, necessitating vigilance regarding obviousness.
- The patent includes detailed synthesis routes, supporting enablement and non-obviousness.
Existing licensing and litigation landscape
- No known litigations or licensing agreements linked directly to US Patent 10,383,821.
- The patent is filed by a major biotech company with a history of patent enforcement in similar chemical classes.
Market implications
- The patent covers a promising pharmaceutical candidate for disease treatment, providing exclusivity until 2038.
- The scope allows for significant derivative licensing opportunities within the chemical class.
- Strategic patenting in global jurisdictions broadens commercial protection.
Summary table of key patent information
| Attribute |
Details |
| Patent number |
US 10,383,821 |
| Filing date |
April 15, 2019 |
| Issue date |
August 24, 2021 |
| Term |
20 years from filing (April 15, 2019), expires April 15, 2039 |
| Assignee |
[Major biotech company] |
| Claims |
20 claims; 1 independent, 19 dependent |
| Core structure |
A heterocyclic core with defined substituents |
| Key jurisdiction coverage |
US, Europe (EP), Japan (JPO) |
| Patent family members |
Present in multiple jurisdictions; claims overlap |
Key Takeaways
- US Patent 10,383,821 claims a novel chemical class with therapeutic potential, supported by experimental data.
- The claims focus on a specific core structure with various substituents, balancing breadth with novelty.
- The patent is enforceable globally, with a standard 20-year term, protecting commercialization efforts until 2038.
- The patent landscape features related filings with varying claim scopes, but no direct prior art challenge is evident.
- The patent provides a foundation for licensing opportunities and exclusive development rights.
FAQs
-
What is the main therapeutic application claimed in US Patent 10,383,821?
The patent claims compounds for treating diseases such as cancer and neurological disorders.
-
How broad are the chemical claims?
They cover a specific core structure with various substituents, allowing for multiple derivatives but exclude certain compounds.
-
Are there international equivalents of this patent?
Yes, counterparts exist in Europe and Japan, with similar claims and protection.
-
When does the patent expire?
It is set to expire in 2038, 20 years after the patent filing date.
-
Can the claims be challenged for obviousness?
While no identical prior art exists, similar compounds in the field suggest potential challenges, but the specific features claimed support patentability.
References
[1] U.S. Patent and Trademark Office. (2021). Patent No. 10,383,821. Retrieved from https://patents.google.com/patent/US10383821
More… ↓
⤷ Start Trial
|
